Recipharm invested €35m to prepare for EU FMD

Contract development and manufacturing organisation (CDMO) Recipharm has announced that all of its facilities are ready for EU serialisation.

The company announced that all fifteen of its facilities in its investment plan were ready for the new EU serialisation laws prior to the 9 February deadline.

Between 2016-1028, Recipharm invested €35 million into its operations and launched a three-year programme so it could offer a serialisation solution to its customers ahead of the introduction of the EU Falsified Medicines Directive (FMD) and the US Drug Supply Chain Security Act (DSCSA).

More so, all of its facilities are connected to customers enabling them to report serial numbers and potentially prevent any counterfeit drugs from making it through the supply chain.

Staffan Widengren, director corporate Ppojects, said: “Recipharm has been very committed to meeting compliance deadlines, establishing a dedicated task force three years ago. A lot of time and effort has gone into our preparations so it’s rewarding to report that we are ready, especially ahead of the enforcement date.”

“Standardising our serialisation capabilities has enabled us to provide a seamless and flexible service to our customers," Widengren added.